Professor of Psychiatry & Beh Sciences @StanfordMed decreasing stigma/increasing evidence/improving care. Food tweets. Digital Ed @BMJMentalHealth Opinions mine
Just had a patient tell me today that my prescribing acamprosate saved his life. Hasn't drank since. "I just don't think about it anymore." Never had someone taking gabapentin tell me that, so just a reminder to all of you out there to follow the data and to watch your biases.😀
My response to John Goulder's hit-piece against me & other critics of antidepressants. It presents itself as 'an account of a quaint, historical controversy..whereas it is actually a partisan intervention in a contemporary and ongoing debate.' joannamoncrieff.wordpress.co…
My response to John Goulder's hit-piece against me & other critics of antidepressants. It presents itself as 'an account of a quaint, historical controversy..whereas it is actually a partisan intervention in a contemporary and ongoing debate.' joannamoncrieff.wordpress.co…
In our latest paper (w/ @seenafazel & @RongqinYu), we have redeveloped the Oxford Mental Illness and Suicide tool (OxMIS) as diagnosis-specific models for schizophrenia-spectrum disorders (n = 48 373) and bipolar disorder (n = 61 684) using nationwide Swedish data, and validated them externally in equivalent data from Finland (n = 52 117 and 30 444, respectively). Discrimination was moderate for schizophrenia-spectrum disorders and good for bipolar disorder, calibration was generally good, and both models showed greater net benefit than treat-all or treat-none strategies at lower risk thresholds. Interestingly, we did not find that adding sociodemographic predictors improved predictive performance.
Full-text: mentalhealth.bmj.com/content…
I updated my post on GLP-1s and muscle mass loss!
A new cohort study found that, at one year, people taking semaglutide tended to lose ~80% of weight as fat, versus 82% for tirzepatide.
Both were comparable to just dieting.
My favorite Marsha Linehan anecdote:
One of my research assistants got into two PhD programs in psychology, one at UW with Linehan, and and chose not to go there. (It was a hard decision.) She called Dr. Linehan to let her know that she was going to the other program. Linehan hung up on her.
Bless her for developing a treatment to help people just like her. Changed treatment forever. RIP.
Marsha Linehan was most validating therapist I've known but also most demanding.
Her "dialectic" means accepting what person feels, but expecting major efforts toward behavioral change.
Both essential. Validation alone justifies not changing. High expectation alone always fails
This is demonstrably false.
In 40 years, there has not been a single lifestyle intervention that, in trials, worked for long-term weight loss.
GLP-1 users lose weight *and* improve their diet.
You guys had nearly a half-century to come up with something, and you didn't.
Nice commentary on a key issue in psychiatric and medical clinical trial design. Functional unblinding and expectancy are not unique to psychedelics, but psychedelic-like drugs are particularly vulnerable to them.
A commentary published in JCP argues that blinding integrity is rarely assessed in trials of drugs with noticeable effects, citing a review in which only 30% of 112 psychedelic and ketamine trials assessed it, and recommends asking patients what they guessed, why, and when. JCP → psychiatrist.com/jcp/functio…#ClinicalTrials#Psychopharmacology#JCP